In the phase III DAWNA-II trial (NCT03966898), patients with HR+/HER2− recurrent or metastatic BC with no prior systemic therapy were randomly assigned (2:1) to receive dalpiciclib plus ET (letrozole or anastrozole) or placebo plus ET. Here, HR is linked to breast cancer.